Cancer resistance evolution was presumed to result from either a pre-existing or acquired
mutation that survives treatment, re-populating the tumour following therapy. However, it …

When metastatic cancers are challenged with targeted agents almost invariably a subset of
cells insensitive to the drug emerges. As a result, in most instances, targeted therapies are …

Despite the continuous deployment of advanced treatment strategies, most disseminated
cancers remain fatal. Like species evolution, cancer is subject to the evolutionary processes …

Despite continuous deployment of new treatment strategies and agents over many decades,
most disseminated cancers remain fatal. Cancer cells, through their access to the vast …

The emergence of acquired drug resistance in cancer represents a major barrier to
treatment success. While research has traditionally focused on genetic sources of …

Many highly effective cancer drugs are available for the treatment of solid tumors but
resistance almost invariably develops. The ability of cancers to acquire drug resistance by …

Acquired drug resistance is a major limitation for the successful treatment of cancer.
Resistance can emerge due to a variety of reasons including host environmental factors as …

Despite the continuous deployment of new treatment strategies and agents over many
decades, most disseminated cancers remain fatal. Cancer cells, through their access to the …

Colorectal cancer (CRC) is one of the most common cancers and one of the leading causes
of cancer related deaths worldwide. CRC is a heterogeneous disease where there can be …

Current standard treatments for metastatic colorectal cancer (CRC) are based on
combination regimens with one of the two chemotherapeutic drugs, irinotecan or oxaliplatin …